Hussein A. Tawbi, MD., Ph.D.

Peer-Reviewed Articles

1. Novis E, Rautalin M, Amaria RN, Ascierto PA, Blank CU, Faries MB, Grunhagen DJ, Gyorki DE, Hayes AJ, Kuijpers AMJ, Long GV, Mammen JMV, Menzies AM, Ross MI, Rutkowski P, Tawbi HA, Tetzlaff MT, Zager JS, Wargo JA, Hieken TJ, van Akkooi ACJ. International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma. Ann Surg Oncol 33(3):2571-2578, 2026. e-Pub 2026. PMID: 41087785.
2. Beckham TH, Dudzinski SO, Rooney MK, Faraj CA, Pasli M, Perni S, Tom M, Ghia A, Yeboa DN, McAleer MF, Swanson T, McGovern S, Wang C, Chung C, De B, Jiang W, Kim BYS, Ferguson SD, Tawbi HA, Glitza I, Le X, Kaya D, Dumbrava EE, Briere T, Mackin D, Li J. Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases. J Natl Compr Canc Netw 24(2):34-40, 2026. e-Pub 2026. PMID: 41671425.
3. Novis E, Rautalin M, Amaria RN, Ascierto PA, Blank CU, Faries MB, Grunhagen DJ, Gyorki DE, Hayes AJ, Kuijpers AMJ, Long GV, Mammen JMV, Menzies AM, Ross MI, Rutkowski P, Tawbi HA, Tetzlaff MT, Zager JS, Wargo JA, Hieken TJ, van Akkooi ACJ. ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 41575642.
4. Moura DS, Lopez-Marti J, Tawbi H, Keung E, Wani K, Lazar A, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess M, Mondaza-Hernandez JL, Hindi N, Martin-Broto J. Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS). Clin Cancer Res, 2026. e-Pub 2026. PMID: 41537707.
5. Kleber TJ, Milton DR, Srinivasan S, Panthi B, Floyd W, Goethe EA, Davies MA, Tawbi HA, Glitza Oliva IC, Kaya D, Li J, Swanson TA, Perni S, Tom MC, Wang C, Prabhu S, Weinberg JS, McCutcheon IE, Chung C, Ferguson SD, Beckham TH. Outcomes of patients with melanoma brain metastases treated with ipilimumab and nivolumab with or without upfront comprehensive stereotactic radiosurgery. Neurooncol Adv 8(1):vdaf276, 2026. e-Pub 2026. PMID: 41664820.
6. Robert M, Saha S, Dizman N, Rohlfs M, Sirmans E, Simon J, Amaria RN, Glitza Oliva IC, Tawbi HA, Davies MA, Ikeguchi A, Basen-Engquist K, Schadler K, Roth ME, Song W, Zhang X, Ajami NJ, Cohen L, Wargo JA, Peterson CB, McQuade JL, Daniel CR. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier. Nutrients 18(1), 2025. e-Pub 2025. PMID: 41515159.
7. Jaffery, R, Zhao, Y, Ahmed, S, Schumacher, JG, Ahn, J, Shi, L, Wang, Y, Tan, Y, Zhang, J, Chen, K, Tawbi, H, Wang, J, Schwarzschild, MA, Peng, W, Chen, X. Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease. npj Parkinson's Disease 11(1), 2025. e-Pub 2025. PMID: 41309625.
8. Long, GV, Garnett-Benson, C, Dolfi, S, Ascierto, PA, Guo, J, Tarhini, AA, Chandra, S, Muñoz-Couselo, E, Del Vecchio, M, De Melo, AC, Callahan, MK, Gogas, H, Dummer, R, Schadendorf, D, Koelblinger, P, Quéreux, G, Thomas, I, Yu, JX, Fisher, A, Wang, B, Djidel, P, Chouzy, A, Semaan, M, Chen, B, Cheong, AM, Tawbi, H. Adjuvant nivolumab and relatlimab in stage III/IV melanoma. Nature medicine 31(12):4301-4309, 2025. e-Pub 2025. PMID: 41109920.
9. Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
10. Grippin, A, Marconi, C, Copling, S, Li, N, Braun, C, Rooney, M, Schrank, B, Gladish, G, Vaporciyan, AA, Johns, AC, Subbiah, IM, Aloia, TA, Wu, J, Wu, CC, Woodman, SE, Weinstein, JN, Tawbi, H, Shete, S, Scheet, PA, Ravi, V, Palaskas, NL, Nates, JL, Muthu, M, Musunuru, TN, McEnery, KW, Litton, J, John, TM, Jaffray, D, Hutcheson, KA, Gunther, J, Godoy, M, Futreal, A, French, KE, Draetta, G, Dabaja, BS, Crommett, JW, Cata, JP, Brock, K, Beird, H, Aaroe, AE, Lee, JJ, Sun, R, Sharma, P, Tran, HT, Zhang, J, Gibbons, DL, Wargo, J, Heymach, JV, Jiang, W, Lin, SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
11. Regan, MM, Ascierto, PA, Lipson, EJ, Palaia, J, Moshyk, A, Selvan, A, Lao, CD, Atkins, MB, McDermott, DF, Potluri, R, Ranjan, S, Bilthare, S, Long, GV, Hodi, FS, Tawbi, H, Schadendorf, D. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. Journal for immunotherapy of cancer 13(9), 2025. e-Pub 2025. PMID: 40940136.
12. Daley, JD, Mukherjee, E, Ferraro, D, Bhaskar, S, Green, A, Meyer, EM, Tawbi, H, Burgess, M, Bruno, TC, Cillo, AR, Bailey, K. SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance. Clinical Cancer Research 31(17):3805-3816, 2025. e-Pub 2025. PMID: 40627445.
13. Daley, JD, Mukherjee, E, Ferraro, D, Bhaskar, S, Green, A, Meyer, EM, Tawbi, H, Burgess, M, Bruno, TC, Cillo, AR, Bailey, K. SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance. Clinical Cancer Research 31(17):3805-3816, 2025. e-Pub 2025. PMID: 40627445.
14. Lipson, EJ, Hodi, FS, Tawbi, H, Schadendorf, D, Ascierto, PA, Matamala, L, Gutiérrez, EC, Rutkowski, P, Gogas, H, Lao, CD, Menezes, JD, Dalle, S, Arance, A, Gaudy-Marqueste, C, Chen, B, Jackson, W, Mukherjee, S, Dolfi, S, Long, GV. Nivolumab plus relatlimab in advanced melanoma. European Journal of Cancer 225, 2025. e-Pub 2025. PMID: 40513285.
15. Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol 43(26):JCO2500494, 2025. e-Pub 2025. PMID: 40638872.
16. Lipson EJ, Dolfi S, Tang H, Tawbi HA, Medina-Soto F, Castillo Gutierrez E, Rutkowski P, Gogas H, Murillo E, Ascierto PA, Desai K, Maio M, Demers K, Mazzei A, Keidel S, Miller-Moslin K, Yu JX, Hodi FS, Schadendorf D, Long GV, Garnett-Benson C. Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047. Clin Cancer Res 31(17):3702-3714, 2025. e-Pub 2025. PMID: 40607902.
17. Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Olofsson Bagge R, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marqueste C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Lev-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Ann Oncol 36(7):807-818, 2025. e-Pub 2025. PMID: 40204154.
18. Yeboa, DN, Li, J, Lin, R, Prabhu, SS, Beckham, TH, Woodhouse, KD, Swanson, T, Weinberg, J, Wang, X, Chi, X, Ejezie, CL, Suki, D, Wang, C, Ene, CI, McCutcheon, IE, McGovern, SL, McAleer, MF, Tom, MC, Ghia, AJ, Perni, S, Jiang, W, De, BS, Chung, C, Kim, BY, O'Brien, BJ, Huse, J, Wefel, JS, Court, LE, Tawbi, H, Janku, F, Guha-Thakurta, N, Debnam, JM, Johnson, JM, Taslicay, CA, Alvarez-Breckenridge, C, Raza, SM, Heimberger, AB, DeMonte, F, North, RY, Briere, TM, de Groot, JF, Sawaya, RE, Grosshans, DR, Lang Jr, FF, Rao, G, Ferguson, SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy. JAMA Oncology 11(8):890-899, 2025. e-Pub 2025. PMID: 40531511.
19. Tawbi HA. Update on LAG3 and immunotherapy combinations in melanoma. Clin Adv Hematol Oncol 23(4):229-231, 2025. e-Pub 2025. PMID: 40590878.
20. Sperduto PW, Marqueen KE, Chang E, Li J, Davies MA, Ebner DK, Breen WG, Lamba N, Shih HA, Edwards D, Kim MM, Mahal A, Rahman R, Ankrah N, Boggs DH, Lewis C, Hyer D, Buatti JM, Johri F, Soliman H, Masucci L, Roberge D, Aneja S, Chiang V, Phuong C, Braunstein S, Dajani S, Sachdev S, Wan Z, Niedzwiecki D, Vaios E, Kirkpatrick JP, Pasetsky J, Wang TJC, Kutuk T, Kotecha R, Ross RB, Rusthoven CG, Nakano T, Tawbi HA, Mehta MP. Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment. J Clin Oncol 43(16):1910-1919, 2025. e-Pub 2025. PMID: 40245362.
21. Gouda, MA, Voss, MH, Tawbi, H, Gordon, MS, Tykodi, SS, Lam, ET, Vaishampayan, U, Tannir, NM, Chaves, J, Nikolinakos, P, Fan, AC, Lee, RJ, McDermott, DF, Shapiro, GI, Gandhi, L, Bhatia, S, Katragadda, V, Meric-Bernstam, F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10(5), 2025. e-Pub 2025. PMID: 40359708.
22. Huang RY, Youssef G, Nelson T, Wen PY, Forsyth P, Hodi FS, Margolin K, Algazi AP, Hamid O, Lao CD, Ernstoff MS, Moschos SJ, Atkins MB, Postow MA, Reardon DA, Grootendorst DJ, Leung D, Askelson M, Ritchings C, Tawbi HA. Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. J Clin Oncol 43(10):1210-1218, 2025. e-Pub 2025. PMID: 39752606.
23. Zhou L, Barros E Silva MJ, Hsiao E, Eroglu Z, Sandhu S, Samoylenko I, Lo SN, Carlino MS, Au-Yeung G, Gonzalez M, Spillane AJ, Pennington TE, Shannon KF, Kapoor R, Burton EM, Tawbi HA, Amaria RN, Blank CU, Duprat JP, Brito de Paula R, Gyorki DE, Saw RPM, Ch'Ng S, Rawson RV, Scolyer RA, Pires da Silva I, Akkooi ACJV, Long GV, Menzies AM. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer 13(3), 2025. e-Pub 2025. PMID: 40132907.
24. Jaffery R, Zhao Y, Ahmed S, Schumacher JG, Ahn J, Shi L, Wang Y, Tan Y, Chen K, Tawbi H, Wang J, Schwarzschild MA, Peng W, Chen X. Soluble Immune Factor Profiles in Blood and CSF Associated with LRRK2 Mutations and Parkinson's Disease. bioRxiv, 2025. e-Pub 2025. PMID: 40196608.
25. Lawson NM, Ye L, Cho CY, Zhao B, Mitchell T, Martin-Barrio I, Beernaert B, Gupta A, Banu M, Lissanu Y, Shaffer S, Tawbi H, Li J, Gule-Monroe MK, Alvarez-Breckenridge CA, Huse JT, Murphy MB, Yin F, Lang FF, Parkes EE, Weinberg JS, Akdemir KC. Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases. medRxiv, 2025. e-Pub 2025. PMID: 40061311.
26. Menzies, AM, Long, GV, Kohn, A, Tawbi, H, Webe, J, Flaherty, KT, McArthur, G, Ascierto, PA, Pfluger, Y, Lewis, K, Tsai, KK, Hamid, O, Prenen, H, Fein, LE, Wang, E, Guenzel, C, Zhang, F, Kleh, JF, Di Pietro, A, Davies, MA. A plain language summary of POLARIS. Future Oncology 21(14):1703-1711, 2025. e-Pub 2025. PMID: 40418081.
27. Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol 43(13):JCO2401124, 2024. e-Pub 2024. PMID: 39671533.
28. Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. J Clin Oncol 42(33):JCO2401125, 2024. e-Pub 2024. PMID: 39137386.
29. Lopez-Olivo MA, Suarez-Almazor ME, Duhon GF, Cherry M, Lu H, Calabrese C, Altan M, Tawbi H, Meara A, Bingham CO, Diab A, Leal VB, Volk RJ. Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study. JMIR Cancer 10:e53443, 2024. e-Pub 2024. PMID: 39454185.
30. Saberian C, Milton DR, Simon J, Amaria RN, Diab A, McQuade J, Patel SP, Tawbi HA, Yee C, Wong MK, McCutcheon IE, Davies MA, Ferguson SD, Glitza Oliva IC. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma. Neurooncol Pract 11(4):452-463, 2024. e-Pub 2024. PMID: 39006528.
31. Turcios Escobar S, Yang R, Nelson KC, Gershenwald JE, Tawbi HA, Aung PP, Patel SP, Torres-Cabala CA. Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. e-Pub 2024. PMID: 38757469.
32. Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Auninš JG, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov:OF1-OF15. e-Pub 2024. PMID: 38588588.
33. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. e-Pub 2024. PMID: 38351182.
34. Jackson-Carroll N, Johnson C, Tawbi H, Wang XS, Whisenant M. The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy. Semin Oncol Nurs 40(1):151574, 2024. e-Pub 2024. PMID: 38220519.
35. Lopez-Olivo, MA, Suarez-Almazor, M, Duhon, GF, Cherry, M, Lu, H, Calabrese, C, Altan, M, Tawbi, H, Meara, A, Bingham, CO, Diab, A, Leal, VB, Volk, R. Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers. JMIR Cancer 10, 2024. e-Pub 2024.
36. Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. Neurooncol Adv 6(1):vdae033, 2024. e-Pub 2024. PMID: 38725995.
37. Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 24(12):e461-e471, 2023. e-Pub 2023. PMID: 37459873.
38. Kirkwood JM, Kottschade LA, McWilliams RR, Khushalani NI, Jang S, Hallmeyer S, McDermott DF, Tawbi H, Che M, Lee CH, Ritchings C, Le TK, Park B, Ramsey S. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. e-Pub 2023. PMID: 37937397.
39. Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL, Nelson KC. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol 159(10):1076-1084, 2023. e-Pub 2023. PMID: 37647056.
40. Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP, Luke JJ, Mitchell TC, Mooradian MJ, Rubin KM, Salama AK, Shirai K, Taube JM, Tawbi HA, Tolley JK, Valdueza C, Weiss SA, Wong MK, Sullivan RJ. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer 11(10), 2023. e-Pub 2023. PMID: 37852736.
41. Augustyn K, Joseph J, Patel AB, Razmandi A, Ali AN, Tawbi HA. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res 33(5):406-416, 2023. e-Pub 2023. PMID: 37534686.
42. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
43. Dummer R, Tawbi H. Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials. Lancet Oncol 24(8):e327, 2023. e-Pub 2023. PMID: 37459871.
44. Tawbi H, Sullivan RJ, Feltquate D, LaVallee T, Rizvi NA, Sharon E, Sosman J, Kluger HM. Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37487665.
45. Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes In Outcomes And Factors Associated With Survival In Melanoma Patients With Brain Metastases. Neuro Oncol 25(7):1310-1320, 2023. e-Pub 2023. PMID: 36510640.
46. Schadendorf D, Tawbi HA, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer 187:164-173, 2023. e-Pub 2023. PMID: 37167764.
47. Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 29(6):1310-1312, 2023. e-Pub 2023. PMID: 37193799.
48. Kreidieh FY, Tawbi HA, Alexaki A, Borghaei H, Kandalaft LE. Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development. Am Soc Clin Oncol Educ Book 43:e391278, 2023. e-Pub 2023. PMID: 37364224.
49. Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol 41(15):JCO2202072, 2023. e-Pub 2023. PMID: 36780608.
50. Lopez-Olivo MA, Duhon GF, Ruiz JI, Altan M, Tawbi H, Diab A, Bingham CO, Calabrese C, Heredia NI, Volk RJ, Suarez-Almazor ME. Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study. Cancers (Basel) 15(10), 2023. e-Pub 2023. PMID: 37345026.
51. Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med 21(1):265, 2023. e-Pub 2023. PMID: 37072748.
52. Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid 2(4):EVIDoa2200239, 2023. e-Pub 2023. PMID: 38320023.
53. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898-905, 2023. e-Pub 2023. PMID: 36997799.
54. Wisinski KB, Flamand Y, Wilson MA, Luke JJ, Tawbi HA, Hong F, Mitchell EP, Zwiebel JA, Chen H, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Behrens RJ, Pennington KP, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precis Oncol 7:e2200421, 2023. e-Pub 2023. PMID: 37053535.
55. Malhotra MK, Pahuja S, Kiesel BF, Appleman LJ, Ding F, Lin Y, Tawbi HA, Stoller RG, Lee JJ, Belani CP, Chen AP, Giranda VL, Shepherd SP, Emens LA, Ivy SP, Chu E, Beumer JH, Puhalla S. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620). Breast Cancer Res Treat 198(3):487-498, 2023. e-Pub 2023. PMID: 36853577.
56. Rizvi N, Ademuyiwa FO, Cao ZA, Chen HX, Ferris RL, Goldberg SB, Hellmann MD, Mehra R, Rhee I, Park JC, Kluger H, Tawbi H, Sullivan RJ. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36918220.
57. Atkins MB, Ascierto PA, Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36918225.
58. Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H, Sharon E. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36918224.
59. Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res 29(3):521-531, 2023. e-Pub 2023. PMID: 36477181.
60. Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O, Clancy T. The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. Front Immunol 14:1226445, 2023. e-Pub 2023. PMID: 37799721.
61. Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
62. Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
63. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
64. Ascierto PA, Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med 20(1):200, 2022. e-Pub 2022. PMID: 35538491.
65. Tawbi HA, Hodi FS, Long GV. Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply. N Engl J Med 386(19):1860-1861, 2022. e-Pub 2022. PMID: 35544394.
66. Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mulé JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res 28(9):1911-1924, 2022. e-Pub 2022. PMID: 35190823.
67. Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. N Engl J Med 386(17):1668-1669, 2022. e-Pub 2022. PMID: 35476655.
68. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
69. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2022. PMID: 34724197.
70. Tawbi HA, Eroglu Z, Anders CK, Margolin KA. Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply. Lancet Oncol 23(2):e54, 2022. e-Pub 2022. PMID: 35114123.
71. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV, Investigators R. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 386(1):24-34, 2022. e-Pub 2022. PMID: 34986285.
72. Tawbi H, To TM, Bartley K, Sadetsky N, Burton E, Haydu L, McKenna E. Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. Cancer Med 11(1):139-150, 2022. e-Pub 2022. PMID: 34874127.
73. Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol:JCO2101601. e-Pub 2022. PMID: 35030011.
74. Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, LaVallee T, Ibrahim R, Wolchok J. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35074903.
75. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
76. Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer 9(11), 2021. e-Pub 2021. PMID: 34782430.
77. Wang J, Tawbi HA. Emergent immunotherapy approaches for brain metastases. Neurooncol Adv 3(Suppl 5):v43-v51, 2021. e-Pub 2021. PMID: 34859232.
78. Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. e-Pub 2021. PMID: 34774225.
79. Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771465.
80. Maguire WF, Schmitz JC, Scemama J, Czambel K, Lin Y, Green AG, Wu S, Lin H, Puhalla S, Rhee J, Stoller R, Tawbi H, Lee JJ, Wright JJ, Beumer JH, Chu E, Appleman LJ, Team ES. Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 88(4):643-654, 2021. e-Pub 2021. PMID: 34164713.
81. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. e-Pub 2021. PMID: 34239137.
82. Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer 153:234-241. e-Pub 2021. PMID: 34225229.
83. Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer 9(5), 2021. e-Pub 2021. PMID: 34021033.
84. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Foundation MR. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res 27(10):2678-2697, 2021. e-Pub 2021. PMID: 33414132.
85. Burton EM, Tawbi HA. Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov 11(5):1008-1010, 2021. e-Pub 2021. PMID: 33947716.
86. Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med 19(1):142, 2021. e-Pub 2021. PMID: 33827575.
87. Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). Neuro Oncol. e-Pub 2021. PMID: 33880555.
88. Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 10(7):2293-2299, 2021. e-Pub 2021. PMID: 33686688.
89. Makawita S, Tawbi HA. Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress. Am Soc Clin Oncol Educ Book 41:79-90, 2021. e-Pub 2021. PMID: 34010041.
90. Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, Wolchok JD. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology 10(1):1898105, 2021. e-Pub 2021. PMID: 33796406.
91. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 27(2):301-309, 2021. e-Pub 2021. PMID: 33558722.
92. Butner JD, Wang Z, Elganainy D, Al Feghali KA, Plodinec M, Calin GA, Dogra P, Nizzero S, Ruiz-Ramírez J, Martin GV, Tawbi HA, Chung C, Koay EJ, Welsh JW, Hong DS, Cristini V. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. e-Pub 2021. PMID: 33398132.
93. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology 10(1):1992880, 2021. e-Pub 2021. PMID: 34777916.
94. Pina Y, Evernden BR, Khushalani N, Margolin K, Tawbi H, Tran ND, Macaulay R, Forsyth P, Peguero E. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. SAGE Open Med Case Rep 9:2050313X211042215, 2021. e-Pub 2021. PMID: 34457306.
95. Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, Scolyer RA, Long GV, Davies MA. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med 9(22):8650-8661, 2020. e-Pub 2020. PMID: 33016647.
96. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbe C, Lugowska I, Mandala M, Marquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol 31(11):1435-1448, 2020. e-Pub 2020. PMID: 32763453.
97. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbe C, Lugowska I, Mandala M, Marquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol 31(11):1449-1461, 2020. e-Pub 2020. PMID: 32763452.
98. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31(11):1569-1579, 2020. e-Pub 2020. PMID: 32739408.
99. Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med 26(10):1557-1563, 2020. e-Pub 2020. PMID: 33020648.
100. Eriksson H, Hansson J, Krynitz B, Masucci G, Girnita A, Lapins J, Huen AO, Tawbi HA, Davies MA, Tetzlaff MT, Curry JL. Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma. Acta Derm Venereol. e-Pub 2020. PMID: 32985676.
101. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. e-Pub 2020. PMID: 32946567.
102. Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 32843491.
103. Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, Patel S, Simon JM, Burton EM, Tawbi H. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32581059.
104. Glitza Oliva IC, Tawbi HA. "Liquid Gold"- The unTAPped potential of cerebrospinal fluid analysis?. Clin Cancer Res 26(9):2083-2084, 2020. e-Pub 2020. PMID: 32139404.
105. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
106. Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32238470.
107. Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi H. Intracranial Anti-Tumor Activity with Encorafenib Plus Binimetinib in Patients with Melanoma Brain Metastases: A Case series. Cancer 126(3):523-530, 2020. e-Pub 2020. PMID: 31658370.
108. Keung EZ, Burgess M, Salazar R, Parra Cuentas E, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno S, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke DK, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. e-Pub 2020. PMID: 31900276.
109. Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Leptomeningeal Disease in Melanoma Patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. e-Pub 2020. PMID: 31916400.
110. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautès-Fridman C, Tawbi HA, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556-560, 2020. e-Pub 2020. PMID: 31942077.
111. Tawbi H. A promising start for checkpoint inhibitors in childhood malignancies. Lancet Oncol 21(1):13-14, 2020. e-Pub 2020. PMID: 31812553.
112. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol:JCO1901508. e-Pub 2020. PMID: 31990608.
113. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
114. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125(23):4193-4202, 2019. e-Pub 2019. PMID: 31398264.
115. Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 84(6):1289-1301, 2019. e-Pub 2019. PMID: 31549216.
116. Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clin Cancer Res 25(21):6406-6416, 2019. e-Pub 2019. PMID: 31371342.
117. Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
118. Christner SM, Parise RA, Ivy PS, Tawbi H, Chu E, Beumer JH. Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal 172:26-32, 2019. e-Pub 2019. PMID: 31022613.
119. Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 25(6):929-935, 2019. e-Pub 2019. PMID: 31171876.
120. Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F. The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018. J Transl Med 17(1):148, 2019. e-Pub 2019. PMID: 31077205.
121. Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142(3):499-509, 2019. e-Pub 2019. PMID: 30847840.
122. Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer 7(1):113, 2019. e-Pub 2019. PMID: 31014399.
123. Abecassis I, Sedgewick AJ, Romkes M, Buch S, Nukui T, Kapetanaki MG, Vogt A, Kirkwood JM, Benos PV, Tawbi H. PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep 9(1):3309, 2019. e-Pub 2019. PMID: 30824778.
124. Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al. J Clin Oncol:JCO1802463. e-Pub 2019. PMID: 30807233.
125. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. e-Pub 2019. PMID: 30787016.
126. Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM. NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer 124(22):4332-4341, 2018. e-Pub 2018. PMID: 30303516.
127. Tawbi HA, Chung C, Margolin K. Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 379(22):2178, 2018. e-Pub 2018. PMID: 30485776.
128. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
129. Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol:JCO1800632. e-Pub 2018. PMID: 30359157.
130. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
131. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
132. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 379(8):722-730, 2018. e-Pub 2018. PMID: 30134131.
133. Keung EZ, Tawbi HA. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!. Cancer Discov 8(8):914-917, 2018. e-Pub 2018. PMID: 30076141.
134. Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol 45(7):545-549, 2018. e-Pub 2018. PMID: 29672900.
135. Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila) 11(7):429-438, 2018. e-Pub 2018. PMID: 29691233.
136. Glitza Oliva IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastases. Ann Oncol 29(7):1509-1520, 2018. e-Pub 2018. PMID: 29790899.
137. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
138. Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3(4), 2018. e-Pub 2018. PMID: 29467321.
139. Tawbi HA, Burgess M, Bolejack V. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology 19(1):E8-E8, 2018. e-Pub 2018.
140. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
141. Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24(1):22-32, 2018. e-Pub 2018. PMID: 29051322.
142. Tawbi HA, Bolejack V, Burgess M, Schuetze S. PD-1 inhibition in sarcoma still needs investigation - Authors' reply. Lancet Oncology 19(1):e7, 2018. e-Pub 2018. PMID: 29304367.
143. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi HA, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
144. Nguyen NC, Yee MK, Tuchayi AM, Kirkwood JM, Tawbi H, Mountz JM. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol 8(18):18, 2018. e-Pub 2018. PMID: 29520339.
145. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi HA, Whitman E, Lee G, Mun Y, Liu S, Hamid O. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res 27(6):585-590, 2017. e-Pub 2017. PMID: 29076950.
146. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology 18(11):1493-1501, 2017. e-Pub 2017. PMID: 28988646.
147. Schvartsman G, Perez K, Sood G, Katkhuda R, Tawbi HA. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma. Annals of Internal Medicine 167(5):361-362, 2017. e-Pub 2017. PMID: 28761949.
148. Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. Journal for Immunotherapy of Cancer 5(1):74, 2017. e-Pub 2017. PMID: 28923120.
149. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi HA, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 18(8):1089-1103, 2017. e-Pub 2017. PMID: 28651927.
150. Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi HA, Li J. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. Journal of Neuro-Oncology 133(3):595-602, 2017. e-Pub 2017. PMID: 28500560.
151. Schvartsman G, Perez K, Flynn JE, Myers JN, Tawbi HA. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. Journal for Immunotherapy of Cancer 5:45, 2017. e-Pub 2017. PMID: 28642816.
152. Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Diaz-Martinez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res 30(3):328-338, 2017. e-Pub 2017. PMID: 28140520.
153. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
154. Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer 123(1):90-97, 2017. e-Pub 2017. PMID: 27696380.
155. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6(12):e1361097, 2017. e-Pub 2017. PMID: 29209563.
156. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
157. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol 78(5):921-927, 2016. e-Pub 2016. PMID: 27681579.
158. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34(8):786-93, 2016. e-Pub 2016. PMID: 26371143.
159. Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6):868-74, 2016. e-Pub 2016. PMID: 26710211.
160. Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34(2):110-6, 2016. e-Pub 2016. PMID: 26392101.
161. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50, 2016. e-Pub 2016. PMID: 27532025.
162. Mesiwala NK, Shemonski N, Sandrian MG, Shelton R, Ishikawa H, Tawbi HA, Schuman JS, Boppart SA, Labriola LT. Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma. J Ophthalmic Inflamm Infect 5(1):53, 2015. e-Pub 2015. PMID: 26285790.
163. Burgess M, Gorantla V, Weiss K, Tawbi H. Immunotherapy in Sarcoma: Future Horizons. Curr Oncol Rep 17(11):52, 2015. e-Pub 2015. PMID: 26423769.
164. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer 112(10):1644-51, 2015. e-Pub 2015. PMID: 25897676.
165. Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov 5(3):264-73, 2015. e-Pub 2015. PMID: 25542447.
166. Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res 21(3):585-93, 2015. e-Pub 2015. PMID: 25473003.
167. Bakkenist CJ, Czambel RK, Hershberger PA, Tawbi H, Beumer JH, Schmitz JC. A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. Oncoscience 2(5):542-54, 2015. e-Pub 2015. PMID: 26097887.
168. Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA. MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics 7(1):58, 2015. e-Pub 2015. PMID: 26052356.
169. Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS One 10(8):e0134426, 2015. e-Pub 2015. PMID: 26247786.
170. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900-9, 2014. e-Pub 2014. PMID: 24523439.
171. Tawbi H. Selective BRAF inhibitors make inroads in mutated metastatic melanoma. J Community Support Oncol 12(2):46-7, 2014. e-Pub 2014. PMID: 24971403.
172. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8 T cells induced by melanoma vaccines. Cancer Res 74(4):1045-55, 2014. e-Pub 2014. PMID: 24343228.
173. Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol 73(1):207-11, 2014. e-Pub 2014. PMID: 24170263.
174. Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 3(1):e27589, 2014. e-Pub 2014. PMID: 24734217.
175. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9(2):e87705, 2014. e-Pub 2014. PMID: 24498358.
176. Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol 72(5):1143-7, 2013. e-Pub 2013. PMID: 24036846.
177. Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal 81-82:89-98, 2013. e-Pub 2013. PMID: 23644904.
178. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol 24(4):1112-9, 2013. e-Pub 2013. PMID: 23172636.
179. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-95, 2012. e-Pub 2012. PMID: 23051966.
180. Shaw PH, Boyiadzis M, Tawbi H, Welsh A, Kemerer A, Davidson NE, Ritchey AK. Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. Cancer 118(14):3614-7, 2012. e-Pub 2012. PMID: 22213134.
181. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30(3):322-8, 2012. e-Pub 2012. PMID: 22184371.
182. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care 16(4):231, 2012. e-Pub 2012. PMID: 22967460.
183. Tawbi HA, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, Shipe-Spotloe J, Radkowski R, Kirkwood JM. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer 105(6):773-7, 2011. e-Pub 2011. PMID: 21811257.
184. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R, Baker LH. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 13(4):459-66, 2008. e-Pub 2008. PMID: 18448562.
185. Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 112(5):1131-8, 2008. e-Pub 2008. PMID: 18286511.
186. Tawbi H, Agarwala SS. Targeted Therapies in Cancer - Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation. IDrugs 8(12):987-9, 2005. e-Pub 2005. PMID: 16320130.
187. Tawbi H, Agarwala SS. Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition. IDrugs 8(12):984-6, 2005. e-Pub 2005. PMID: 16320129.

Invited Articles

1. Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. e-Pub 2019. PMID: 30712316.
2. Tawbi HA, Boutros C, Kok D, Robert C, McArthur G. New Era in the Management of Melanoma Brain Metastases. Am Soc Clin Oncol Educ Book(38):741-750, 2018. e-Pub 2018. PMID: 30231345.
3. Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol 16(6):26, 2015. e-Pub 2015. PMID: 25975445.
4. Gorantla V, Kirkwood JM, Tawbi HA. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep 15(5):483-91, 2013. e-Pub 2013. PMID: 23954973.
5. Tran A, Tawbi HA. A potential role for nilotinib in KIT-mutated melanoma. Expert Opin Investig Drugs 21(6):861-9, 2012. e-Pub 2012. PMID: 22500535.
6. Tawbi HA, Buch SC. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 8(4):259-66, 2010. e-Pub 2010. PMID: 20505649.
7. Tawbi HA, Nimmagadda N. Targeted therapy in melanoma. Biologics 3:475-84, 2009. e-Pub 2009. PMID: 20054438.
8. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 34(6):532-45, 2007. e-Pub 2007. PMID: 18083377.
9. Chugh R, Tawbi HA, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: The Nonsarcoma Primary Bone Tumor. The Oncologist 12(11):1344-50, 2007. e-Pub 2007. PMID: 18055855.

Review Articles

1. Mattei, J, Ruitao, L, Davies, MA, Wong, MK, Diab, A, Haydu, LE, Patel, SP, Amaria, RN, McQuade, JL, Tawbi, H, Burton, EM, Glitza, IC. Adjuvant therapy in mucosal melanoma. Melanoma research 36(1):31-42, 2026. e-Pub 2026. PMID: 41337670.
2. Valiente M, Anders C, Boire A, Izar B, Kotecki N, Malladi S, Massague J, Moss NS, Neman J, Preusser M, Schagen S, Siegel PM, Tawbi H, Venkataramani V, Winkler F, Zadeh G, Joyce JA. The evolving landscape of brain metastasis: volume II. Trends Cancer 12(2):116-146, 2026. e-Pub 2026. PMID: 41339184.
3. Ileana Dumbrava, EE, Frej, KH, Sharon, E, Tawbi, H. Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. Annual Review of Medicine 76:189-205, 2025. e-Pub 2025. PMID: 39656959.
4. Anders CK, Van Swearingen AED, Neman J, Joyce JA, Cittelly DM, Valiente M, Zimmer AS, Floyd SR, Dhakal A, Sengupta S, Ahluwalia MS, Nagpal S, Kumthekar PU, Emerson S, Basho R, Beal K, Moss NS, Razis ED, Yang JT, Sammons SL, Sahebjam S, Tawbi HA. Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases. Neurooncol Adv 7(1):vdaf049, 2025. e-Pub 2025. PMID: 40276376.
5. Le Rhun E, Weller M, Anders C, Larkin J, Li J, Moss NS, Tawbi H, Dummer R. "Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools. Eur J Cancer 208:114202, 2024. e-Pub 2024. PMID: 38991283.
6. Pellerino A, Davidson TM, Bellur SS, Ahluwalia MS, Tawbi H, Rudà R, Soffietti R. Prevention of Brain Metastases: A New Frontier. Cancers (Basel) 16(11), 2024. e-Pub 2024. PMID: 38893253.
7. Amouzegar A, Haig S, Kahn AM, Tawbi HA, Jones JA, Goldberg SB. Navigating the Complexities of Brain Metastases Management. Am Soc Clin Oncol Educ Book 44(3):e433694, 2024. e-Pub 2024. PMID: 38781565.
8. Amouzegar A, Tawbi HA. Local and Systemic Management Options for Melanoma Brain Metastases. Cancer J 30(2):102-107, 2024. e-Pub 2024. PMID: 38527263.
9. Kim MM, Mehta MP, Smart DK, Steeg PS, Hong JA, Espey MG, Prasanna PG, Crandon L, Hodgdon C, Kozak N, Armstrong TS, Morikawa A, Willmarth N, Tanner K, Boire A, Gephart MH, Margolin KA, Hattangadi-Gluth J, Tawbi H, Trifiletti DM, Chung C, Basu-Roy U, Burns R, Oliva ICG, Aizer AA, Anders CK, Davis J, Ahluwalia MS, Chiang V, Li J, Kotecha R, Formenti SC, Ellingson BM, Gondi V, Sperduto PW, Barnholtz-Sloan JS, Rodon J, Lee EQ, Khasraw M, Yeboa DN, Brastianos PK, Galanis E, Coleman CN, Ahmed MM. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. Lancet Oncol 24(8):e344-e354, 2023. e-Pub 2023. PMID: 37541280.
10. Rahman R, Polley MC, Alder L, Brastianos PK, Anders CK, Tawbi HA, Mehta M, Wen PY, Geyer S, de Groot J, Zadeh G, Piantadosi S, Galanis E, Khasraw M. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol 24(4):e161-e171, 2023. e-Pub 2023. PMID: 36990614.
11. Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol 15:17588359231186027, 2023. e-Pub 2023. PMID: 37484526.
12. Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 35(6):554-572, 2022. e-Pub 2022. PMID: 35912544.
13. Kreidieh FY, Tawbi HA. Current and emerging options for patients with melanoma brain metastases. Clin Adv Hematol Oncol 20(10):619-627, 2022. e-Pub 2022. PMID: 36206074.
14. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 11(6):1368-1397, 2021. e-Pub 2021. PMID: 33811048.
15. Tawbi H. The standard of care for brain metastases in melanoma. Clin Adv Hematol Oncol 18(1):28-31, 2020. e-Pub 2020. PMID: 32511219.
16. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Consortium members INM, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 20(7):e378-e389, 2019. e-Pub 2019. PMID: 31267972.
17. Glitza Oliva I, Tawbi H, Davies MA. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J 23(1):68-74, 2017. e-Pub 2017. PMID: 28114258.
18. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 29(6):627-642, 2016. e-Pub 2016. PMID: 27615400.
19. Kirkwood JM, Tarhini A, Sparano JA, Patel P, Schiller JH, Vergo MT, Benson Iii AB, Tawbi H. Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev 39(1):27-43, 2013. e-Pub 2013. PMID: 22520262.
20. Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 19(23):3907-21, 2012. e-Pub 2012. PMID: 22788767.
21. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5(3):196-208, 2010. e-Pub 2010. PMID: 20406169.
22. Arayssi TK, Tawbi HA, Usta IM, Hourani MH. Calcitonin in the Treatment of Transient Osteoporosis of the Hip. Semin Arthritis Rheum 32(6):388-97, 2003. e-Pub 2003. PMID: 12833247.

Other Articles

1. Salim HA, Msherghi A, Learned K, Zafereo M, Wang J, Dagher SA, Altintas Taslicay C, Dagher R, Alizada S, Hu MI, Cabanillas ME, Busaidy N, Hamidi S, Tawbi H, Li J, Ucisik FE, Wintermark M Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid 35(12):1378-1390, 2025. PMID: 40956665.
2. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. PMID: 30995944.

Editorials

1. Massi D, Tawbi H. Optimizing pathological response assessment after neoadjuvant immunotherapy: linking clinical practice to drug development. Ann Oncol 37(2):139-140, 2026. PMID: 41565433.
2. Tarhini AA, Tawbi H, Storkus WJ. Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma. Melanoma Manag 3(4):251-254, 2016. PMID: 30190895.
3. Tawbi HA. Combination therapies for treating metastatic melanoma. Clin Adv Hematol Oncol 13(4):211-4, 2015. PMID: 26352577.
4. Tawbi HA. Matching wits with melanoma brain metastases: from biology to therapeutics. Clin Cancer Res 20(21):5346-8, 2014. PMID: 25135484.
5. Tawbi HA, Kirkwood JM. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol 9(9):496-7, 2012. PMID: 22889973.
6. Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?. Nat Clin Pract Oncol 6(2):70-1, 2009. PMID: 19092800.

Abstracts

1. Tawbi HA, Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, Rutkowski P, Gogas H, Lao CD, De Menezes JJ, Dalle S, Arance AM, Grob J, Ratto , Rodriguez S, Xu Y, Wang P, Dolfi S, Long GV. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047, 2023. e-Pub 2023.
2. Dummer R, Long GV, Postow M, Ribas A, Robert C, Scolyer RA, Taube JM, Tetzlaff M, Su SC, Ahsan S, Diede SJ, Tawbi HA. KEYmAKER-U02: Phase 1/2 Study of Investigational Agents With of Without Pembrolizumab or Pembrolizumab Monotherapy in Melanoma, 2020. e-Pub 2020.
3. Maurer DM, Santos P, Kirkwood JM, Tarhini AA, Tawbi HA, Stroncek D, Jin P, Butterfield LH. Dysregulation of immune modulating molecules and signaling pathways in dendritic cells/DC-based vaccines generated from advanced-stage melanoma patients. Journal of Translational Medicine 17, 2019. e-Pub 2019.
4. Amaria RN, Trinh VA, Gu J, McIntyre S, Cabala CT, Simien R, Diab A, Tawbi HA, Davies MA, Wong MK, Hwu P, Glitza IC, Patel SP, Hwu WJ. Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM), 2018. e-Pub 2018.
5. Gasal E, Fernandez AMA, Ascierto PA, Atkinson V, Dummer R, Flaherty KT, Grob JJ, Hansson J, Hassel J, Larkin J, Lebbe C, Long GV, Lorigan P, Miller W, Nathan P, Ribas A, Robert C, Schadendorf D, Tawbi, HT, Upalawanna A. A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i). Annals of Oncology 28, 2017. e-Pub 2017.
6. Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, Cornfeld M, Swann S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies MA, Overwijk W, Bernatchez C, Hwu P. A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. 42nd European Society for Medical Oncology Congress (ESMO) 28, 2017. e-Pub 2017.
7. Tarhini AA, Frankel PH, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, McDermott DF, Chen A, Lara PN, Kirkwood JM. NCI 8628-A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma, 2017. e-Pub 2017.
8. Chen WS, Cameron M, Spencer C, Tawbi HA, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Journal of Clinical Oncology 35, 2017. e-Pub 2017.
9. McKean MA, Haydu LE, Ma JS, Bassett RL, Hwu WJ, Patel SP, Diab A, Glitza IC, Tawbi HA, Wong MK, McQuade JL, Hwu P, Davies MA, Amaria RN. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
10. Tawbi HA, Forsyth PA, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Gonzalez R, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini AA, Jiang J, Avila A, Demelo S, Margolin KA. Efficacy of safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
11. Patel SP, Glitza IC, Diab A, Amaria RN, Davies MA, Hwu P, Tawbi HA, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM). Journal of Clinical Oncology 35, 2017. e-Pub 2017.
12. Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu WJ, Hwu P, Woodman SE, Tetzlaff MT, Milton D, Perez K, Davies MA, Rai K, Wargo JA, Tawbi HA. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM). Journal of Clinical Oncology 35, 2017. e-Pub 2017.
13. Burgess MA, Bolejack V, Van Tine BA, Schuetze S, Hu J, D'Angelo SP, Attia S, Priebat DA, Okuno SH, Riedel RF, Davis LE, Mowa S, Reed DR, Butterfield LH, Roszik J, Reinke DK, Baker LH, Maki RG, Patel S, Tawbi HA. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
14. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel SP, Davies MA, Tawbi HA, Glita IC. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
15. Shaw AC, Trinh VA, Bassett RL, Glitza IC, Diab A, Amaria RN, Tawbi HA, Davies M, Hwu WJ, Hwu P, Patel SP. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. J Clin Oncol 34, 2016. e-Pub 2016.
16. Tarhini AA, Rahman Z, Pryanka V, Tawbi HA, Gnan A, McFadden A, Rose A, Pruckner C, Wilson M, Pingpank JF, Hotzman MP, Ferris RL, Rao UNM, Kirkwood JM. Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma. J Clin Oncol 34, 2016. e-Pub 2016.
17. Barcena E, Trinh VA, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HA, Davies MA, Hwu WJ. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
18. Burgess MA, Nathenson M, Kasi PM, Khalil L, Ross M, Tawbi HA. A case series of sarcoma brain metastases (SBM): A single-institution experience. J Clin Oncol 34, 2016. e-Pub 2016.
19. Davar D, Wang H, Chauvin JM, Sun Z, Pagliano O, Rose A, Muniz C, Sander C, Fourcade JJ, Rao UNM, Ibrahim N, Ebbighaus S, Tawbi HA, Tarhini AA, Kirkwood JM, Zarour HM, Russo G. Phase 1B study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL). ASCO Annual Meeting 2016, 2016. e-Pub 2016.
20. Tawbi HA, Burgess MA, Crowley J, Van Tine BA, Hu J, Scott S, D'Angelo SP, Attia S, Priebat DA, Okuno SH, Riedel RF, Davis LE, Movva S, Reed DR, Baker LH, Reinke DK, Maki RG, Patel S. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARCO28-A multicenter phase II study. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
21. Rohlfs M, Bassett RL, Lacey C, McQuail N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HA, Davies M, Hwu WJ, Hwu P, Patel SP. BRAF with or without MEK inhibition plus PD-1 checkpoint blocade for the treatment of metastatic melanoma. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
22. Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, Hwu WJ, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HA, Woodman SE, Wargo JE, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, HWU P. A phase I/ii study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CSCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). j Clin Oncol 34, 2016. e-Pub 2016.
23. Krikwood JM, Sing S, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UNM, Sander C, Tarhini AA, Tawbi HA, Ferris L, Wilson M, Petrany M, Rose A, Fahey JW, Leachman SA, Cassidy P, Butterfield LH, Zarour HM. Does-response evaluation of brocolli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplatic nevi (A/DN). J Clin Oncol, 2016. e-Pub 2016.
24. Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D'Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (pts) with advanced sarcomas. J Clin Oncol(33), 2015. e-Pub 2015.
25. Yee MK, Lin Y, Gorantla VC, Butterfield LH, Kluger HM, Chapman PB, Gangadhar TC, Milhem MM, Pavlic AC, Amaravadi RK, Schuter LM, Tarhini AA, Kirkwood JM, Tawbi HA. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metasteses (coBRIM-B). J Clin Oncol(33), 2015. e-Pub 2015.
26. Pahuja S, Beumer JH, Appleman LJ, Tawbi HA, Stoller RG, Lee JJ, Lin Y, Ding F, Yu J, Belani CP, Chen AP, Giranda VL, Shepherd SP, Chu E, Puhalla S. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol 33, 2015. e-Pub 2015.
27. Zarour HM, Tawbi HA, Tarhini AA, Wang H, Sander C, Rose A, Fourcade JJ, Chauvin JM, Sun Z, Paliano O, Kirkwood JM. Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. ASCO 2015 Annual Meeting, 2015. e-Pub 2015.
28. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze S, Staddon AP, Milhem MM, Elias AD, Ganjoo KN, Tawbi HA, Van Tine BA, Spira AL, Dean AP, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel S. A randomized phase III study of travectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomysarcoma (LMS). J Clin Oncol(33), 2015. e-Pub 2015.
29. Margolin KA, Tawbi HA, Enstoff MS, Hodi FS, McDermott DF, Edward R, Avila A, Atkins MB. A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. J Clin Oncol(33), 2015. e-Pub 2015.
30. Carvajal RD, Agulink M, Ryan CW, Mihem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi HA, Elias AD, Read WL, Budd GT, Himan J, Weiden P, Bennett CM, Livingston PO, Hansen D, Maki RG, Schwartz GK, Chugh R. Tirvalent gangsliode vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. J Clin Oncol 32(5s), 2014. e-Pub 2014.
31. Puhalla S, Beumer JH, Pahuja S, Appleman LJ, Tawbi HA, Stoller RG, Lee JJ, Lin Y, Kiesel B, Yu J, Tan AR, Belani CP, Chew HK, Garcia AA, Morgan R, Giranda VL, Shepherd SP, Chen AP, Chu E. Final results of a phase 1 study of single-agent velipariv (V) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinium-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol 32(5s), 2014. e-Pub 2014.
32. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel N, Wilczynski S, Christensen S, Gandara DR, Chow WA. NCI:8412 A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas. Presented at the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
33. Ashraf M, Kirkwood JM, Emsloft MS, Tawbi HA, Frankel PH, Ruel N, Kendra KL, Olencki T, Khushalani NI, Logan TF, Ka M, Chen AP, Tarhini AA. NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma - efficacy and biomarker study. Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5s), 2014. e-Pub 2014.
34. Tawbi HA, Chu E, Lin Y, Hyman D, Goel S, Rudek M, Dowlati A, LoRusso P, Mulkerin D, Chew H, Chung V, Harvey D, Shapiro G, Belani C, Applemenn L, Puhalla S, Stoller R, Lee J, Pollice L, Ivy P, Beumer JH. Early phase I study of PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction-a study of the NCI-organ dysfunction working group (OGD). Presented at the 50th American Society fo Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
35. Davies MA, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfield LH, Hamilton RL, Armankulor N, Engh JA, Shivalingham B, Kefford R, Scoyler RA, Mahmood S, Richards-Peterson LE, Swann S, Arbushities MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamics analysis of preoperative therapy with dabrafenib alone and in combination with trametinic in patients wish BRAF mutation-posisitve melanoma with metastases to the brain (BRV116521). Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5s), 2014. e-Pub 2014.
36. Tarhini AA, Lin Y, Lin H, LaFrambroise WA, Rao UNM, Tawbi HA, Ashraf M, Pingpank JF, Holtzman MP, Sciulli C, Sander C, Kirkwood JM. A unique gene expression signature in tumor positive or negative sentinel lymph nodes in patients with melanoma. Journal of Clinical Oncology, Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5S), 2014. e-Pub 2014.
37. Davar D, Saul M, Trent K, Holtzman MP, Edington H, Tawbi HA, Tarhini AA, Kirkwood JM. Prognostic significance of sentinel lymph node biopsies (SLNB) in melanoma. J Clin Oncol 32, 2014. e-Pub 2014.
38. Davar D, Tarhini AA, Tawbi HA, Ferrone S, Zarour HM, Kirkwood JM. Dose seeking and efficacy study of combination BRAFi and high-dose IFN(HDI) therapy for therapy of advanced melanoma. J Clin Oncol 32(5s), 2014. e-Pub 2014.
39. Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty K, Lee SJ, Lee A, Pandit K, Abecassis I, Nathanson KL, Benos PV, Tawbi HA. microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603. J Clin Oncol 32(5s), 2014. e-Pub 2014.
40. Sedgewick AJ, Romkes M, Buch S, Villaruz L, Abecassis I, Saul M, Kirkwood JM, Benos PV, Tawbi HA. PARP1 variants associated with response to temozolomide chemotherapy in melanoma. Markers in Cancer 2013: Joint Meeting by ASCO &EORTC & NCI (#MC13-0078), 2013. e-Pub 2013.
41. Gangadhar TC, Xu X, Karakousis G, Amaravadi RK, Haas N, Kudchadkar R, Pavlick A, Sosman JA, Tawbi HA, Walker L, Schuchter LM. Multi-institution phase I study of BRAF (vemurafenib) and P13K inhibition (PX-866) in advanced BRAF mutant solid tumors in melanoma. Society of Melanoma Research, Oral Presentation, 2013. e-Pub 2013.
42. Tarhini AA, LaFramboise WA, Rao UNM, Edington H, Pingpank JF, Hotzman MP, Tawbi HA, Geskin A, Rose A, Milburn C, Merriman M, Sander C, Sciulli C, Lin Y, Kirwood JM. Differential genomic profiles of tumor-involved and tumor-free sentinel lymph nodes in patients with melanoma. ASCO 2013 Annual Meeting, 2013. e-Pub 2013.
43. Davar D, Saul M, Tarhini AA, Tran A, Trent K, Sander C, Kirkwood JM, Tawbi H. High-dose interleukin-2 (HD-IL2) in the treatment of advanced melanoma: The University of Pittsburgh experience. ASCO 2013 Annual Meeting, 2013. e-Pub 2013.
44. Tarhini AA, Edington H, Butterfield LH, Tawbi H, Moschos SJ, Shuai Y, Lin Y, Horak M, Sarkisian S, Shipe-Spotloe J, Milburn C, Sander C, Johnson JT, Kirkwood JM. Neoadjuvant ipilimumab in locally/regionally advanced in melanoma: clinical outcome and immune monitoring. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
45. Huggins-Puhalla SL, Beumer JH, Appleman LJ, Tawbi HA, Stoller RG, Lin Y, Kiesel B, Tan AR, Gibbon D, Jian Y, Garcia A, Chew HK, Morgan R, Shepherd SP, Giranda VL, Chen AP, Belani CP, Chu E. A phase I study of chornically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt). ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
46. Carvajal RD, Chugh R, Milhem MM, Ryan CW, George S, Chmielowski B, Agulnik M, Rodler ET, Elias AD, Budd GT, Tawbi H, Movva S, Van Tine BA, Dickinson MA, Hensley ML, Keohan MIL, Tap WD, Bennett CM, Maki RG, Schwartz GK. Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
47. Krauze MT, Hamilton RH, Romkes M, Boroluzzi S, Harasymczuk M, Reinhard T, Junecko BF, Nukui T, Konstantinopoulos P, Becker D, Kondziolka D, Tarhini AA, Whiteside T, Mintz AH, Tawbi H, Ferrone S, Kirkwood JM, Moschos SJ. Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
48. Appleman LJ, Beumer JH, Jian Y, Puhalla S, Lin Y, Owonikoko TK, Harvey RD, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Kiesel B, Chu E, Shepherd SP, Giranda VL, Chen AP, Belani CP, Ramalingam SS. A phase I study of veliparib (ABT-888) in combinatin with carboplatin and paclitaxel in advanced solid malignancies. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
49. Rios-Perez JA, Beumer JH, Appleman LJ, Tawbi HA, Chu E, Stoller RG, Belani CP, Jian Y, Sobol RW, Shepherd SP, Giranda VL, Chen AP, Huggins-Puhalla SL. ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
50. Lobur D, Davar D, Singh S, Beumer JH, Edington H, Tarhini AA, Tawbi H, Zarour HM, Talalay P, Kirkwood JM. Pilot evaluation of sulforaphane in melanoma patients with multiple atypical nevi: Tissue STAT1 and STAT3 as risk markers. ASCO 2012 Annual Meeting, 2012. e-Pub 2012.
51. Tarhini AA, Edington H, Butterfield LH, Sinha M, Moschos SJ, Tawbi H, Shuai Y, Shipe-Spotloe J, Simonetta M, Milburn, Horak M, Sander C, Kirkwood JM. Neoadjuvant ipilimumab in patients with stage IIIb. ASCO 2011 Annual Meeting, 2011. e-Pub 2011.
52. Beumer JH, Tawbi HA, Tarhini AA, Moschos SJ, Egorin MJ, Buch SC, Lin Y, Kirkwood JM. Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM). ASCO Annual Meeting, 2011. e-Pub 2011.
53. Tawbi HA, Rodon Anhert J, Dummer R, Thomas AL, Granvil C, Shou Y, Dey J, Mita MM, Amakye DD, Mita AC. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. ASCO Annual Meeting, 2011. e-Pub 2011.
54. Schuetze SM, Wathen K, Choy E, Ganjoo KN, Chow WA, Staddon AP, Samuels BL, Tawbi H, Patel S, Demetri G, Baker LH. SARC009: Results of a SARC Phase II trial of dasatinib in alveolar soft part sarcoma, chondrosarcoma, chordoma, epitheliod sarcoma and hemangiopercytoma. CTOS Annual Meeting, 2010. e-Pub 2010.
55. Rodon J, Baselga J, Tawbi HA, Shou Y, Feng W, Dummer R, Mahalingam D, Thomas A, Amakye D, Mita AC. Phase I safety and pharmacologic results in patients with advanced solid tumors. ESMO Congress 2010, 2010. e-Pub 2010.
56. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Egorin MJ, Buch S, Lin YC, Lin Y, Kirkwood JM. Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM). ASCO 2010 Annual Meeting, 2010. e-Pub 2010.
57. Rodon Ahnert J, Baselga J, Tawbi HA, Shou Y, Granvil C, Dey J, Mita MM, Thomas AL, Amakye DD, Mita AC. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. ASCO 2010 Annual Meeting, 2010. e-Pub 2010.
58. Tarhini AA, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Phase II evaluation of tremelimuma (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. ASCO 2010 Annual Meeting, 2010. e-Pub 2010.
59. Tawbi HA, Lin YC, Villaruz L, Egorin MJ, Beumer JH, Buch S, Kirkwood JM, Soboll RW. Enhanced cytotoxicity of carboplatin and paclitaxel (CP) by vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, in melanoma cell lines. AACR 101ST 2010 Annual Meeting, 2010. e-Pub 2010.
60. Tarhini A, Christensen S, Frankel P, Margolin K, Ruel C, Tawbi HA, Shipe-Spotloe J, DeMark M, Kirkwood JM. Phase II study of afilibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or cular origin. ASCO 2009 Annual Meeting, 2009. e-Pub 2009.
61. Tawbi HA, Buch S, Pancoska P, Lin Y, Saul M, Romkes M, Sobol R, Kirkwood J. Prediction of response to alkylator-based chemothrapy in metastatic melanoma (MM) using gene expression and promoter methylation signatures. ASCO 2009 Annual Meeting, Oral Presentation, 2009. e-Pub 2009.
62. Tawbi HA, Papachristou D, Buch S, Michalopoulos G, Rao U. Ewing's sarcoma (EWS) and synovial sarcoma (SS) have distinct microRNA expression profiles. AACR 2009 Annual Meeting, 2009. e-Pub 2009.
63. Tawbi HA, Tarhini A, Moschos S, Sulecki M, Viverette F, Radkowski R, Shipe-Spotloe J, Kunkel C, Rae M, Kirkwood J. Phase I trial of lomeguatrib (Patrin, PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part 1, 24(18S (June 20 Supplement)), 2006. e-Pub 2006.
64. Sobol RW, Tawbi HA, Jukic DM, Mule K, Mascari R, Kirkwood JM. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to darbazine (DTIC)/Temozolomide (TMZ) therapy of patients with metastatic melanoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1, Vol 24(18S, June 20 Supplement), 2006. e-Pub 2006.
65. Ng YH, Tawbi HA, Granieri R. A sore throat gone awry. Society of General Internal Medicine under the category of "Unknown Clinical Vignette", 2005. e-Pub 2005.

Book Chapters

1. Margolin K, Davies M, Kluger H, Tawbi HA. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. In: Cutaneous Melanoma. Springer Ling, 2019.
2. Tawbi H, Kirkwood JM. Riegel, Cancer of the Skin. In: Imaging of the Melanoma Patient. Second, 2011.

Books (edited and written)

1. Tawbi, H. Best Practices in the Treatment and Management of Melanoma, 2023.
2. Shui, IM, Scherrer, E, Frederickson, A, Li, JW, Mynzhassarova, A, Druyts, E, Tawbi, H. Resistance to anti-PD1 therapies in patients with advanced melanoma, 2022.
3. Rosenbaum, E, Chugh, R, Ryan, CW, Agulnik, M, Milhem, M, George, S, Jones, RL, Chmielowski, B, Van Tine, BA, Tawbi, H, Elias, A, Read, WL, Budd, GT, Qin, LX, Rodler, E, Hirman, J, Weiden, PL, Bennett, CM, Livingston, PO, Ragupathi, G, Hansen, D, D'Angelo, S, Tap, WD, Schwartz, GK, Maki, RG, Carvajal, R. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery, 2022.
4. Dummer, R, Tawbi, H. Symptomatic melanoma CNS metastases in the TRICOTEL study – Authors' reply, 2022.
5. Ho, J, Mattei, J, Tetzlaff, M, Williams, MD, Davies, MA, Diab, A, Glitza, IC, McQuade, JL, Patel, SP, Tawbi, H, Wong, MK, Fisher, SB, Hanna, EY, Keung, EZ, Ross, MI, Weiser, R, Su, SY, Frumovitz, M, Meyer, LA, Jazaeri, AA, Pettaway, CA, Guadagnolo, BA, Bishop, AJ, Mitra, D, Farooqi, AS, Bassett Jr, R, Faria, SC, Nagarajan, P, Amaria, RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma, 2022.
6. Aizer, A, Lamba, N, Ahluwalia, MS, Aldape, K, Boire, A, Brastianos, PK, Brown, P, Camidge, DR, Chiang, V, Davies, MA, Hu, LS, Huang, R, Kaufmann, TJ, Kumthekar, P, Lam, K, Lee, EQ, Lin, NU, Mehta, MP, Parsons, MW, Reardon, DA, Sheehan, J, Soffietti, R, Tawbi, H, Weller, M, Wen, PY. Brain metastases, 2022.
7. Dummer, R, Queirolo, P, Abajo Guijarro, AM, Hu, Y, Wang, D, Azevedo, SJ, Robert, C, Ascierto, PA, Chiarion-Sileni, V, Pronzato, P, Spagnolo, F, Mujika Eizmendi, K, Liszkay, G, de la Cruz-Merino, L, Tawbi, H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL), 2022.
8. Van Akkooi, AC, Hieken, TJ, Burton, EM, Ariyan, C, Ascierto, PA, Asero, SV, Blank, CU, Block, MS, Boland, GM, Caracò, C, Ch'Ng, S, Davidson, BS, Duprat Neto, JP, Faries, MB, Gershenwald, JE, Grunhagen, D, Gyorki, DE, Han, D, Hayes, AJ, Van Houdt, WJ, Karakousis, G, Klop, WM, Long, GV, Lowe, MC, Menzies, AM, Bagge, RO, Pennington, TE, Rutkowski, P, Saw, RP, Scolyer, RA, Shannon, K, Sondak, V, Tawbi, H, Testori, A, Tetzlaff, M, Thompson, JF, Zager, JS, Zuur, CL, Wargo, J, Spillane, A, Ross, MI. Correction to, 2022.
9. Tawbi, H, Robert, C, Brase, JC, Gusenleitner, D, Gasal, E, Garrett, J, Savchenko, A, Gorgun, G, Flaherty, KT, Ribas, A, Dummer, R, Schadendorf, D, Long, GV, Nathan, P, Ascierto, PA. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma, 2022.
10. Van Akkooi, AC, Hieken, TJ, Burton, EM, Ariyan, C, Ascierto, PA, Asero, SV, Blank, CU, Block, MS, Boland, GM, Caracò, C, Ch'Ng, S, Davidson, BS, Duprat Neto, JP, Faries, MB, Gershenwald, JE, Grunhagen, D, Gyorki, DE, Han, D, Hayes, AJ, Van Houdt, WJ, Karakousis, G, Klop, WM, Long, GV, Lowe, MC, Menzies, AM, Olofsson Bagge, R, Pennington, TE, Rutkowski, P, Saw, RP, Scolyer, RA, Shannon, K, Sondak, V, Tawbi, H, Testori, A, Tetzlaff, M, Thompson, JF, Zager, JS, Zuur, CL, Wargo, J, Spillane, A, Ross, MI. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma, 2022.
11. Manzo, J, Puhalla, S, Pahuja, S, Ding, F, Lin, Y, Appleman, LJ, Tawbi, H, Stoller, RG, Lee, JJ, Diergaarde, B, Kiesel, BF, Yu, J, Tan, AR, Belani, C, Chew, HK, Garcia, AA, Morgan, RJ, Hendrickson, AW, Visscher, D, Hurley, RM, Kaufmann, SH, Swisher, EM, Oesterreich, S, Katz, TA, Ji, J, Zhang, Y, Parchment, R, Chen, A, Duan, W, Giranda, V, Shepherd, SP, Ivy, SP, Chu, E, Beumer, JH. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer, 2022.
12. Tawbi, H, Burton, EM, Haydu, LE, Bartley, K, Seetasith, A, Lee, J, McKenna, EF, Kent, M. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma, 2022.

Letters to the Editor

1. Beumer JH, Tawbi HA, Ivy SP. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol 34: 2430-1, 2016.